Meet the Experts Transporter Conference Webinar - Gaining Mechanistic Insight in Drug Induced Cholestasis: What Can We Learn from Bile Acid Profiling in Human Hepatocytes?

Meet the Experts Transporter Webinar - Gaining Mechanistic Insight in Drug Induced Cholestasis: What Can We Learn from Bile Acid Profiling in Human Hepatocytes?


Welcome


Like much of the world, we are limiting our travel and putting face-to-face meetings on hold as a result of the COVID-19 pandemic. The pace of scientific progress continues however, and with it the need for discourse and debate. Since taking the difficult decision to postpone our Meet the Experts Transporter Conference at the start of the year, we have received a significant level of interest from our colleagues in the transporter field for an alternative venue in which to showcase the latest in transporter research. We are therefore delighted to announce the start of the SOLVO Biotechnology Meet the Experts Transporter Webinar Series!


Timing


Date: 22 June 2022

8:00 am (PT)

11:00 am (ET)

4:00 pm (GMT)

5:00 pm (CET)

6:00 pm (IST)

12:00 pm (Beijing)

01:00 am (Tokyo, Seoul)


Abstract


Gaining Mechanistic Insight in Drug Induced Cholestasis: What Can We Learn from Bile Acid Profiling in Human Hepatocytes?

Preclinical prediction of drug induced cholestasis liability remains a major drug development challenge. In recent years, several in vitro models have been developed and applied to achieve a better risk assessment regarding the drug induced cholestasis potential of novel drug candidates. Vesicle-based models allowing high throughput assessment of interaction with the activity of the bile salt export pump (BSEP, ABCB11) have become a standard assay when screening drug candidates. In addition, holistic models for detecting compounds with a cholestatic signature have emerged. Several hepatocyte-based models have been developed relying on a toxicity/viability endpoint (e.g. urea production or ATP content) after incubations of test compounds in the absence or presence of bile acid mixtures. Meanwhile, it has become clear that the network of mechanisms underlying drug-induced cholestasis remains elusive and extends far beyond BSEP inhibition alone. In this context, our research group has invested in the generation of in vitro data regarding the disposition of bile acids in sandwich-cultured cultured human hepatocytes, including the disturbance by the signature cholestatic drug bosentan. The aim of this webinar is to first provide an overview of the state-of-the-art regarding bile acid profiling in cultured hepatocytes. Secondly, this webinar will address how altered bile acid profiles may provide future opportunities for developing improved in vitro models for understanding and predicting drug-induced cholestasis.

Selected references:

Chatterjee, S., Richert, L., Augustijns, P. & Annaert, P. Hepatocyte-based in vitro model for assessment of drug-induced cholestasis. Toxicol Appl Pharm 274, 124–136 (2014).

Brantegem, P. V., Deferm, N., Qi, B., Vocht, T. D. & Annaert, P. Experimental Cholestasis Research. Methods Mol Biology 1981, 55–73 (2019).

Deferm, N. et al. Current insights in the complexities underlying drug-induced cholestasis. Crit Rev Toxicol 49, 1–29 (2019).

Brantegem, P. V., Chatterjee, S., Bruyn, T. D., Annaert, P. & Deferm, N. Drug-induced cholestasis assay in primary hepatocytes. Methodsx 7, 101080 (2020).

Oorts, M. et al. Bosentan alters endo- and exogenous bile salt disposition in sandwich-cultured human hepatocytes. J Pharmacol Exp Ther 379, JPET-AR-2021-000695 (2021).


Speakers


ANNAERT Pieter, PharmD., PhD.

ANNAERT Pieter, PharmD., PhD.

Professor of Pharmacokinetics, Chair of the Department of Pharmaceutical and Pharmacological Sciences, KU Leuven

Biography

Pieter Annaert is a pharmacist by training and obtained his PhD in pharmaceutical Sciences at KU Leuven in 1998. He conducted 2 years of postdoctoral research in the field of in vitro hepatic drug disposition at the University of North Carolina at Chapel Hill. After some years at Janssen Pharmaceutica, in the division of preclinical pharmacokinetics, he moved to KU Leuven in 2005, where he currently is full professor at the Drug Delivery and Disposition Lab. Since 2020 he is the chair of the KU Leuven Department of Pharmaceutical and Pharmacological Sciences. In 2017 he co-founded the CRO BioNotus, specialized in bioanalysis, pharmacometrics and Discovery ADMET.

His research interests are in the field of Mechanistic Pharmacokinetics. This includes the development and application of in vitro models of the liver, as well as physiology based pharmacokinetic modelling and simulation. In addition, his team has particular interest in predicting and understanding perinatal pharmacology and drug-induced cholestasis.


Recording


Please click here to download the presentation!